financetom
Business
financetom
/
Business
/
Gap raises annual sales target betting on steady holiday demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gap raises annual sales target betting on steady holiday demand
Nov 21, 2024 6:53 PM

Nov 21 (Reuters) - Gap Inc ( GAP ) raised its annual sales forecast on Thursday,

signaling steady demand for the Old Navy parent's casual wear apparel, as the holiday season

approaches.

With shoppers budgeting to purchase trendy styles, Gap's strategy of paring back discounts

and stocking fresher, popular items in its stores has helped the company appeal to a broader

customer base.

The Banana Republic owner reported sales growth for a fourth consecutive quarter as it

executes a turnaround under CEO Richard Dickson, who took on the role in August 2023.

Gap now expects full-year net sales to rise between 1.5% and 2%, compared with its earlier

target of marginal growth.

Dickson has emphasized returning to the company's roots as a "pop culture brand," creating

marketing campaigns for its casual wear that focus on music and fashion, such as "Get Loose."

The holiday period was off to a "strong start," Dickson said in a statement, after the

company's third-quarter net sales rose 2% to $3.8 billion, aligned with estimates.

Gap's Old Navy brand has also been gaining back lost ground with fresher styles for denim

and dresses appealing to customers at full price, with similar gains reflecting in Athleta, its

athletic wear unit.

The company raised its gross margin expansion target for the year by 20 basis points, after

reporting a 140 basis point increase in gross margin for the quarter ended Nov. 2.

Gap earned third-quarter profit per share of 72 cents, compared with analysts' estimate of

58 cents, as per data compiled by LSEG.

Athletic apparel maker Under Armour ( UAA ) also raised its annual profit forecast earlier

in November as CEO Kevin Plank's turnaround plan to offer popular designs at full price helps

drive demand.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved